144 related articles for article (PubMed ID: 36982309)
1. A Sulfur Containing Melanogenesis Substrate,
Tamura Y; Ito A; Wakamatsu K; Torigoe T; Honda H; Ito S; Jimbow K
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982309
[No Abstract] [Full Text] [Related]
2. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
[TBL] [Abstract][Full Text] [Related]
3. The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its n-acetyl derivative.
Miura T; Jimbow K; Ito S
Int J Cancer; 1990 Nov; 46(5):931-4. PubMed ID: 2121652
[TBL] [Abstract][Full Text] [Related]
4. 4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma.
Ito A; Fujioka M; Yoshida T; Wakamatsu K; Ito S; Yamashita T; Jimbow K; Honda H
Cancer Sci; 2007 Mar; 98(3):424-30. PubMed ID: 17270032
[TBL] [Abstract][Full Text] [Related]
5. Comparison of in vivo anti-melanoma effect of enantiomeric alpha-methyl- and alpha-ethyl-4-S-cysteaminylphenol.
Yukitake J; Otake H; Inoue S; Wakamatsu K; Ito S
Melanoma Res; 2004 Apr; 14(2):115-20. PubMed ID: 15057040
[TBL] [Abstract][Full Text] [Related]
6. Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis.
Minamitsuji Y; Toyofuku K; Sugiyama S; Yamada K; Jimbow K
J Investig Dermatol Symp Proc; 1999 Sep; 4(2):130-6. PubMed ID: 10536987
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminylphenol, a tyrosinase substrate, in melanoma models.
Ito S; Nishigaki A; Ishii-Osai Y; Ojika M; Wakamatsu K; Yamashita T; Tamura Y; Ito A; Honda H; Nakayama E; Jimbow K
Biochem Pharmacol; 2012 Sep; 84(5):646-53. PubMed ID: 22728921
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and selective in vitro anti-melanoma effect of enantiomeric alpha-methyl- and alpha-ethyl-4-S-cysteaminylphenol.
Yukitake J; Otake H; Inoue S; Wakamatsu K; Olivares C; Solano F; Hasegawa K; Ito S
Melanoma Res; 2003 Dec; 13(6):603-9. PubMed ID: 14646624
[TBL] [Abstract][Full Text] [Related]
9. Selective in vivo accumulation of N-acetyl-4-S-cysteaminylphenol in B16F10 murine melanoma and enhancement of its in vitro and in vivo antimelanoma effect by combination of buthionine sulfoximine.
Alena F; Iwashina T; Gili A; Jimbow K
Cancer Res; 1994 May; 54(10):2661-6. PubMed ID: 8168094
[TBL] [Abstract][Full Text] [Related]
10. [Development of targeted chemoradiotherapy for malignant melanoma by exploitation of metabolic pathway].
Jimbow K
Hokkaido Igaku Zasshi; 1998 Mar; 73(2):105-10. PubMed ID: 9612704
[TBL] [Abstract][Full Text] [Related]
11. Selective in vivo and in vitro incorporation and accumulation of phenolic thioether amine into malignant melanoma and identification of a (58 kD) binding glycoprotein.
Yamada K; Jimbow K
Melanoma Res; 1992 Nov; 2(4):225-33. PubMed ID: 1490110
[TBL] [Abstract][Full Text] [Related]
12. Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity.
Gili A; Thomas PD; Ota M; Jimbow K
Melanoma Res; 2000 Feb; 10(1):9-15. PubMed ID: 10711635
[TBL] [Abstract][Full Text] [Related]
13. Comparison of antimelanoma effects of 4-S-cysteaminylphenol and its homologues.
Inoue S; Hasegawa K; Wakamatsu K; Ito S
Melanoma Res; 1998 Apr; 8(2):105-12. PubMed ID: 9610862
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
15. Antimelanoma effect of 4-S-cysteaminylcatechol, an activated form of 4-S-cysteaminylphenol.
Inoue S; Hasegawa K; Ito S; Ozeki H; Solano F; Jiménez-Cervantes C; Wakamatsu K; Fujita K
Cancer Res; 1995 Jun; 55(12):2603-7. PubMed ID: 7780975
[TBL] [Abstract][Full Text] [Related]
16. Action of cysteaminylphenols on human melanoma cells in vivo and in vitro: 4-S-cysteaminylphenol binds protein disulphide isomerase.
Parsons PG; Favier D; McEwan M; Takahashi H; Jimbow K; Ito S
Melanoma Res; 1991; 1(2):97-104. PubMed ID: 1823629
[TBL] [Abstract][Full Text] [Related]
17. In vivo antimelanoma effects of 4-S-cysteaminylphenol, a newly synthesized therapeutic agent specific to melanoma.
Kitagawa M; Nemoto T; Seki S; Ito S; Kasuga T
J Cancer Res Clin Oncol; 1993; 119(8):470-4. PubMed ID: 8099588
[TBL] [Abstract][Full Text] [Related]
18. Selective cytotoxicity of 4-S-cysteaminylphenol on follicular melanocytes of the black mouse: rational basis for its application to melanoma chemotherapy.
Ito Y; Jimbow K
Cancer Res; 1987 Jun; 47(12):3278-84. PubMed ID: 3107807
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol.
Prezioso JA; Wang N; Bloomer WD
Cancer Chemother Pharmacol; 1992; 30(5):394-400. PubMed ID: 1505078
[TBL] [Abstract][Full Text] [Related]
20. Dihydro-1,4-benzothiazine-6,7-dione, the ultimate toxic metabolite of 4-S-cysteaminylphenol and 4-S-cysteaminylcatechol.
Hasegawa K; Ito S; Inoue S; Wakamatsu K; Ozeki H; Ishiguro I
Biochem Pharmacol; 1997 May; 53(10):1435-44. PubMed ID: 9260870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
